Argatroban

Generic Name: Argatroban

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₃₆N_₆O_₅S

CAS Number: 74863-84-6

Unique Ingredient Identifier: OCY3U280Y3

Background: Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant shown to both normalize platelet count in ...

Indication: Argatroban is indicated for prevention and treatment of thrombosis caused by heparin-induced thrombocytopenia (HIT). It is also indicated for use in patients with, or at risk for, HIT who are undergoing percutaneous coronary intervention.

Associated Conditions: Thrombosis

Associated Therapies: -

Clinical Trials

Safety and Feasibility of Argatroban, Tissue Plasminogen Activator and Intra-arterial Therapy in Stroke

Phase 2

Completed

Conditions: Cerebral Ischemia
Stroke

Interventions: Drug: Argatroban

First Posted Date: 2015-05-19

Last Posted Date: 2017-06-21

Lead Sponsor: The University of Texas Health Science Center, Houston

Target Recruit Count: 10

Registration Number: NCT02448069

Locations: 🇺🇸
University of Texas Health Science Center at Houston, Houston, Texas, United States

Argatroban for Preventing Occlusion and Restenosis After Extracranial Vertebral Artery Stenting

Phase 4

Completed

Conditions: CVD

Interventions: Drug: Argatroban
Drug: non-argatroban treated group

First Posted Date: 2013-11-08

Last Posted Date: 2015-10-23

Lead Sponsor: Xinfeng Liu

Target Recruit Count: 114

Registration Number: NCT01980316

Locations: 🇨🇳
Department of Neurology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu, China

Argatroban in Critically Ill Patients With Heparin Resistance

Phase 2

Completed

Conditions: Achievement of a Sufficient Thrombosis Prohpylaxis in Clitically Ill Patients With Heparin Resistance

Interventions: Drug: Argatroban

First Posted Date: 2012-11-27

Last Posted Date: 2017-11-17

Lead Sponsor: Medical University Innsbruck

Target Recruit Count: 44

Registration Number: NCT01734252

Locations: 🇦🇹
Medical University Innsbruck / Department for General and Surgical Intensive Care Medicine, Innsbruck, Austria

Retrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II

Completed

Conditions: Acute HIT II (Heparin-induced Thrombocytopenia Type II)

Interventions: Drug: fondaparinux
Drug: lepirudin
Drug: danaparoid
Drug: argatroban

First Posted Date: 2011-02-25

Last Posted Date: 2017-07-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 195

Registration Number: NCT01304238

Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting

Phase 4

Completed

Conditions: CVD

Interventions: Drug: Argatroban
Drug: non-argatroban treated group

First Posted Date: 2010-07-16

Last Posted Date: 2015-11-23

Lead Sponsor: Jinling Hospital, China

Target Recruit Count: 114

Registration Number: NCT01163604

Locations: 🇨🇳
Department of Neurology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu, China

Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II

Phase 2

Completed

Conditions: Heparin-induced Thrombocytopenia Type II

Interventions: Drug: argatroban

First Posted Date: 2009-03-13

Last Posted Date: 2016-08-01

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 20

Registration Number: NCT00861692

Argatroban Versus Lepirudin in Critically Ill Patients

Phase 4

Terminated

Conditions: Heparin Induced Thrombocytopenia (HIT)

Interventions: Drug: Argatroban
Drug: Lepirudin

First Posted Date: 2008-11-26

Last Posted Date: 2012-06-21

Lead Sponsor: Heinrich-Heine University, Duesseldorf

Target Recruit Count: 70

Registration Number: NCT00798525

Locations: 🇩🇪
Universitätsklinikum Düsseldorf Klinik für Anästhesiologie, Düsseldorf, Germany

Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)

Phase 2

Completed

Conditions: Coronary Artery Disease
Angina, Unstable

Interventions: Drug: Argatroban
Drug: Heparin

First Posted Date: 2007-07-30

Last Posted Date: 2012-12-05

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 140

Registration Number: NCT00508924

Argatroban Stroke Treatment - A Pilot Safety Study

Phase 1

Completed

Conditions: Ischemic Stroke

Interventions: Drug: argatroban

First Posted Date: 2005-12-22

Last Posted Date: 2014-11-10

Lead Sponsor: The University of Texas Health Science Center, Houston

Target Recruit Count: 65

Registration Number: NCT00268762

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
University of Alabama-Birmingham, Birmingham, Alabama, United States
🇺🇸
Memorial Hermann Hospital-Medical Center, Houston, Texas, United States

and more 3 locations

Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia

Phase 3

Completed

Conditions: Heparin-Induced Thrombocytopenia

First Posted Date: 2005-09-20

Last Posted Date: 2008-11-13

Lead Sponsor: Ministry of Health, Labour and Welfare, Japan

Target Recruit Count: 8

Registration Number: NCT00198588

Locations: 🇯🇵
Kyoto University Hospital, Kyoto, Japan
🇯🇵
The University of Tokyo Hospital, Tokyo, Japan
🇯🇵
Nagoya University Hospital, Nagoya, Aichi, Japan

and more 17 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy